Facebook
facebook

With AFSTYLA, You May Dose Twice Weekly

Enhanced half-life extends time to 1% factor level

The 14.2-hour half-life of AFSTYLA allows the flexibility to dose 2 or 3 times a week, depending on your needs.

  • In patients ≥12 years, median time to trough levels of 1% total Factor VIII activity has been estimated to be between 4 and 5 days, depending on dose and extrapolation method.1
  • The half-life of AFSTYLA in people younger than 12 years was 10.3 hours

Half-life measures how long it takes for the activity level of your infused factor to drop by 50%. A longer half-life means that the drug is active in your body for a longer time.

Factor VIII activity chart

Dosing AFSTYLA twice weekly helped Jonathan & his dad

"One less infusion means a world of difference to a parent."*

–Hector, Father of Jonathan

*Speaker's personal experience. Individual results may vary.

AFSTYLA dosing

The recommended dosing range for routine prophylaxis is:

  • 20–50 IU/kg of AFSTYLA for adults and adolescents (≥12 years)
  • 30–50 IU/kg of AFSTYLA for children (<12 years)

In clinical trials, the median dose was:

  • 2 times a week
    • 35 IU/kg for people of all ages
  • 3 times a week
    • 30 IU/kg for people ≥12 years
    • 32 IU/kg for people <12 years

FDA approved for dosing 2 times a week and 3 times a week

Proven protection with a low average dose

Low doses may mean less volume per dose and less time for each infusion.

purple connector

Simplified storage and administration

Room temperature storage for up to 3 months (not to exceed 77°F)
Once stored at room temperature, do not return the product to the refrigerator. You can also store in the refrigerator (36°F to 46°F) up to the expiration date.
Reconstituting AFSTYLA is fast and simple
AFSTYLA uses the Mix2Vial® needle-free reconstitution and transfer system.

Learn about the innovative Mix2Vial® reconstitution and transfer system

Mix2Vial® is a registered trademark of West Pharma. Services IL, Ltd., a subsidiary of West Pharmaceutical Services, Inc.

Thinking about a switch in therapy?

Here are some
things to consider

Reference: 1. Data on file. Available from CSL Behring as DOF AFS-001.

You are now leaving the current website.

Do you want to continue?

No Yes